Local and regional recurrence following mastectomy in breast cancer patients with 1–3 positive nodes: implications for postmastectomy radiotherapy volume

다국어 초록 (Multilingual Abstract)

Purpose: To determine the necessity of postmastectomy radiotherapy (PMRT) and which regions would be at risk for recurrence, we evaluated local and regional recurrence in breast cancer patients with 1–3 positive nodes and a tumor size of <5 cm.
Materials and Methods: We retrospectively analyzed data of 133 female breast cancer patients with 1–3 positive nodes, and a tumor size of <5 cm who were treated with mastectomy followed by adjuvant systemic therapy between 2007 and 2016. The median follow-up period was 57 months (range, 12 to 115 months). Most patients (82.7%) were treated with axillary lymph node dissection.
Adjuvant chemotherapy, endocrine therapy, and trastuzumab therapy were administered to 124 patients (93.2%), 112 (84.2%), and 33 (24.8%), respectively. The most common chemotherapy regimen was anthracycline and cyclophosphamide followed by taxane (71.4%).
Results: Three patients (2.3%), 8 (6.0%), and 12 (9.0%) experienced local, regional, and distant failures, respectively. The 5-year cumulative risk of local recurrence, regional recurrence, distant metastasis, and disease-free survival was 3.1%, 8.0%, 11.7%, and 83.4%, respectively. There were no statistically significant clinicopathologic factors associated with local recurrence. Lymphovascular invasion (univariate p = 0.015 and multivariate p = 0.054) was associated with an increased risk of regional recurrence.
Conclusion: Our study showed a very low local recurrence in patients with 1–3 positive nodes and tumor size of <5 cm who were treated with mastectomy and modern adjuvant systemic treatment. The PMRT volume need to be tailored for each patient’s given risk for local and regional recurrence, and possible radiation-related toxicities.

참고문헌 (Reference)

1 Rakha EA, "The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice" 64 : 609-615, 2014

2 Goldhirsch A, "Strategies for subtypes: dealing with the diversity of breast cancer:highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011" 22 : 1736-1747, 2011

3 Truong PT, "Selecting breast cancer patients with T1-T2tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy" 61 : 1337-1347, 2005

4 Darby SC, "Risk of ischemic heart disease in women after radiotherapy for breast cancer" 368 : 987-998, 2013

5 Katz A, "Recursive partitioning analysis of locoregional recurrence patterns following mastectomy: implications for adjuvant irradiation" 50 : 397-403, 2001

6 Ceilley E, "Radiotherapy for invasive breast cancer in North America and Europe: results of a survey" 61 : 365-373, 2005

7 Barry M, "Radiotherapy and breast reconstruction: a meta-analysis" 127 : 15-22, 2011

8 Sharma R, "Present-day locoregional control in patients with T1 or T2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy" 17 : 2899-2908, 2010

9 Ge Wen, "Predictive Value of Molecular Subtyping for Locoregional Recurrence in Early-Stage Breast Cancer with N1 without Postmastectomy Radiotherapy" 한국유방암학회 19 (19): 176-184, 2016

10 김연주, "Postmastectomy Radiotherapy in Patients with pT1-2N1 Breast Cancer Treated with Taxane-Based Chemotherapy: A Retrospective Multicenter Analysis (KROG 1418)" 대한암학회 49 (49): 927-936, 2017

11 Taghian A, "Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials" 22 : 4247-4254, 2004

12 Mamounas EP, "Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28" 23 : 3686-3696, 2005

13 National Comprehensive Cancer Network, "NCCN Clinical Practice Guidelines in Oncology: breast cancer (Version 1.2018)" National Comprehensive Cancer Network

14 Paszat LF, "Mortality from myocardial infarction following postlumpectomy radiotherapy for breast cancer: a populationbased study in Ontario, Canada" 43 : 755-762, 1999

15 Darby SC, "Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries" 6 : 557-565, 2005

16 Lai SF, "Locoregional recurrence risk for postmastectomy breast cancer patients with T1-2and one to three positive lymph nodes receiving modern systemic treatment without radiotherapy" 23 : 3860-3869, 2016

17 McBride A, "Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3positive lymph nodes treated with mastectomy and systemic treatment" 89 : 392-398, 2014

18 Ragaz J, "Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial" 97 : 116-126, 2005

19 Recht A, "Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group" 17 : 1689-1700, 1999

20 Overgaard M, "Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials" 82 : 247-253, 2007

21 Reisenbichler ES, "Interobserver concordance in implementing the 2010 ASCO/CAP recommendations for reporting ER in breast carcinomas: a demonstration of the difficulties of consistently reporting low levels of ER expression by manual quantification" 140 : 487-494, 2013

22 Jagsi R, "Impact of radiotherapy on complications and patient-reported outcomes after breast reconstruction" 110 : 157-165, 2018

23 Tendulkar RD, "Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1-3 positive lymph nodes treated with modern systemic therapy" 83 : e577-e581, 2012

24 EBCTCG, "Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality:meta-analysis of individual patient data for 8135 women in 22 randomised trials" 383 : 2127-2135, 2014

25 Sartor CI, "Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344" 23 : 30-40, 2005

26 Chang JS, "Do recent advances in diagnostic and therapeutic procedures negate the benefit of postmastectomy radiotherapy in N1 patients with a low risk of locoregional recurrence?" 94 : e1259-, 2015

27 Yu JI, "Determining which patients require irradiation of the supraclavicular nodal area after surgery for N1 breast cancer" 78 : 1135-1141, 2010

28 Early Breast Cancer Trialists' Collaborative Group, "Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials" 379 : 432-444, 2012

29 Chang JH, "Chest wall recurrence in pT1-2N0-1 breast cancer patients after mastectomy without radiotherapy" 169 : 507-512, 2018

30 Ragaz J, "Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer" 337 : 956-962, 1997